Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor beta variable 4-1 (TRBV4-1)
- Target
- TRBV4-1
- Molecular classification
- Receptor (cell surface), T cell receptor family (TCR/T cell receptor superfamily), Immunoglobulin superfamily (by domain structure)
01
Overview
T cell receptor beta variable 4-1 is a protein-coding gene segment encoding the variable region of the beta chain of the T cell receptor complex. This region contributes to antigen specificity; T cell receptors recognize peptides presented by major histocompatibility complexes on antigen-presenting cells. TRBV4-1 participates in signal transduction leading to T cell activation and immune effector functions and is part of a highly diverse receptor family generated through gene rearrangement in the thymus. Its variability allows for effective immune surveillance and response, but may also contribute to immune-mediated diseases. There are no approved drugs that directly target TRBV4-1, although TCRs incorporating this segment may be used in research and cellular therapy contexts.
- Other names
- TRBV4-1TCRBV7S1A1N2TTRBV41TCRBV4S1BV07S1J2.7T-cell receptor beta chain V region 86T1V_segment translation product
02
Mechanism of action
For drugs or biologics leveraging TCR specificity: Engage antigen recognition, immune synapse formation, T cell activation, cytokine release, cytotoxic response.
03
Biological functions
Signal transduction (initiating downstream pathways upon antigen recognition)Immune response (antigen recognition, T cell activation)Regulation of cell proliferation and differentiation in T cells
04
Disease associations
Cancer (especially roles in immunotherapy via engineered TCRs)Infection (recognition and clearance of pathogens)Autoimmunity (aberrant T cell activation)Inflammation (immune regulation)
05
Safety considerations
Off-target T cell activation (autoimmunity)Cytokine-release syndrome in adoptive T cell therapies (where engineered TCRs may include TRBV4-1 sequences)Immunopathology due to cross-reactivity
06
Interacting drugs
No direct approved drugs target TRBV4-1 specifically. Drugs or biologics (e.g., engineered TCRs, certain bispecific antibodies, CAR-T cell designs, immune checkpoint inhibitors) may use knowledge of TCR beta chain variability, but TRBV4-1 is not a specific approved drug target
07
Biomarkers
T cell receptor V beta chain usage is exploited as a research biomarker in studies of clonal T cell expansions (e.g., for monitoring minimal residual disease, autoimmune responses, or infection-specific immune profiling)
Beyond the preview
Go deeper on T cell receptor beta variable 4-1 (TRBV4-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T cell receptor beta variable 4-1 (TRBV4-1).